.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,371,406

« Back to Dashboard

Details for Patent: 7,371,406

Title:Preparation of injectable suspensions having improved injectability
Abstract: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20.degree. C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
Inventor(s): Ramstack; J. Michael (Lunenburg, MA), Riley; M. Gary I. (Cambridge, MA), Zale; Stephen E. (Hopkinton, MA), Hotz; Joyce M. (Cincinnati, OH), Johnson; Olufunmi L. (Cambridge, MA)
Assignee: Alkermes Controlled Therapeutics, Inc. (Cambridge, MA)
Filing Date:Oct 09, 2003
Application Number:10/681,142
Claims:1. A method for preparing a composition suitable for injection through a needle into a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; and (b) mixing the first suspension with a viscosity enhancing agent to form a second suspension, wherein the viscosity enhancing agent increases viscosity of a fluid phase of the second suspension to be in the range of from about 20 cp to about 600 cp at 20.degree. C., wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host through a needle ranging in diameter from 18-22 gauge.

2. The method of claim 1, wherein the viscosity of the fluid phase of the second suspension after step (b) is from about 200 cp to about 600 cp at 20.degree. C.

3. The method of claim 1, wherein the concentration of microparticles in the first suspension is greater than about 300 mg/ml and less than about 400 mg/ml.

4. The method of claim 1, wherein a viscosity of the viscosity enhancing agent is from about 1000 to about 2000 cp at 20.degree. C.

5. The method of claim 1, wherein the viscosity enhancing agent comprises sodium carboxymethyl cellulose.

6. The method of claim 1, wherein a volume of the viscosity enhancing agent mixed with the first suspension is approximately 10-25% of the volume of the first suspension.

7. The method of claim 1, further comprising before step (b): (c) withdrawing the first suspension into a first syringe.

8. The method of claim 7, wherein step (b) comprises: (i) providing a second syringe containing the viscosity enhancing agent; (ii) coupling the first syringe to the second syringe so that fluid can pass between the first and second syringes; and (iii) repeatedly passing the first suspension and the viscosity enhancing agent between the first and second syringes.

9. A method for administering a composition to a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; (b) mixing the first suspension with a viscosity enhancing agent to form a second suspension, wherein the viscosity enhancing agent increases viscosity of a fluid phase of the second suspension to be in the range of from about 20 cp to about 600 cp at 20.degree. C. wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host; and (c) injecting the second suspension into the host through a needle ranging in diameter from 18-22 gauge.

10. A method for administering a composition to a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a suspension, wherein the injection vehicle has a viscosity at 20.degree. C. of less than about 60 cp, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; (b) changing the viscosity of a fluid phase of the suspension to be in the range of from about 20 cp to about 600 cp at 20.degree. C. wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host; (c) withdrawing the suspension into a syringe; and (d) injecting the suspension from the syringe into the host through a needle ranging in diameter from 18-22 gauge.

11. The method of claim 10, wherein step (b) comprises: changing the temperature of the fluid phase of the suspension.

12. The method of claim 10, wherein step (c) is performed prior to step (b), and step (b) comprises: adding a viscosity enhancing agent to the suspension in the syringe to thereby increase the viscosity of the fluid phase of the suspension.

13. The method of claim 12, wherein the viscosity enhancing agent comprises sodium carboxymethyl cellulose.

14. The method of claim 9, wherein the microparticles comprise an active agent.

15. A method of making a composition suitable for injection through a needle into a host, comprising: (a) providing microparticles comprising a polymeric binder; (b) providing an injection vehicle having a viscosity of at least 20 cp at 20.degree. C.; and (c) suspending the microparticles in the injection vehicle to form a suspension, wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml, wherein the viscosity of a fluid phase of the suspension is in the range of from about 20 cp to about 600 cp at 20.degree. C., wherein the viscosity of the fluid phase of the suspension provides injectability of the composition into the host through a needle ranging in diameter from 18-22 gauge.

16. The method of claim 10, wherein step (c) is performed prior to step (b).

17. A method for preparing a composition suitable for injection through a needle into a host, comprising: (a) mixing dry microparticles with an injection vehicle to form a first suspension, wherein the microparticles comprise a polymeric binder and wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml; and (b) mixing the first suspension with a viscosity enhancing agent to form a second suspension, wherein the viscosity enhancing agent increases viscosity of a fluid phase of the second suspension to be in the range of from about 20 cp to about 600 cp at 20.degree. C., wherein the viscosity of the fluid phase of the second suspension provides injectability of the composition into the host through a needle of medically acceptable size.

18. The method of claim 17, wherein an internal diameter of the needle ranges from about 700 to about 400 microns.

19. A method of making a composition suitable for injection through a needle into a host, comprising: suspending microparticles comprising a polymeric binder in an injection vehicle having a viscosity of at least 20 cp at 20.degree. C. to form a suspension, wherein the microparticles are suspended in the injection vehicle at a concentration of from about 175 mg/ml to about 400 mg/ml, wherein the viscosity of a fluid phase of the suspension is in the range of from about 20 cp to about 600 cp at 20.degree. C., wherein the viscosity of the fluid phase of the suspension provides injectability of the composition into the host through a needle of medically acceptable size.

20. The method of claim 19, wherein an internal diameter of the needle ranges from about 700 to about 400 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc